A breakthrough drug for treating the most common type of lung cancer was just approved by the Food and Drug Administration ahead of schedule following two successful clinical trials, including one that involved patients at Providence Cancer Center in Portland.
People with B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia have a unique opportunity to participate in groundbreaking research at Providence Cancer Center.
Cancer survivors and researchers shared the stage at Providence Cancer Center’s 15th annual “Positive Perspectives: Creating Hope for Cancer Patients Luncheon” May 15 at the Oregon Convention Center.
Patients with advanced melanoma are getting a boost from work being done at Providence, thanks to a grant from the National Institutes of Health.
Providence's involvement with the International Immuno-Oncology Network, along with other early-phase studies, is broadening treatment options for patients with advanced cancers.
Providence is the only cancer facility in Oregon to receive QOPI certification.
Safeway customers and employees in Oregon and Southwest Washington raised $500,000 for breast cancer awareness, treatment and research at Providence.
Providence Cancer Center is among North America's top research institutions invited to join the national Cancer Immunotherapy Trials Network.
Ipilimumab is the first drug shown to extend survival in patients with late-stage melanoma.